ADLIB
LIVE

Serial Number

79169309

Owner

Chiome Bioscience Inc.

Attorney

Jeffrey H. Handelsman

Filing Date

Apr 28, 2015

Add to watchlist:

No watchlists yet
View on USPTO

ADLIB Trademark

Serial Number: 79169309 • Registration: 5139363

ADLIB is a trademark filed by Chiome Bioscience Inc. on April 28, 2015. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Chiome Bioscience Inc. (3 trademarks)

3-12-1 Honmachi
Tokyo 151-0071 , JP

Entity Type: 03

Trademark Details

Filing Date

April 28, 2015

Registration Date

February 14, 2017

Published for Opposition

November 29, 2016

Goods & Services

[ Research, product development and quality control services in the field of proteins, antibodies, microorganisms and cells, and consultancy relating thereto; research and development services in the field of antibody technology; biomedical research services; design and development of medical technology; research and development in the field of biotechnology; pharmaceutical research and development; conducting clinical trials for others in the field of pharmaceutical products; clinical trials for others; technical project studies in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical research in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical project planning in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; research and development of new products for others; design and development of computer software for use with medical technology; software design and development; providing temporary use of non-downloadable business software; rental of computer software; cloud computing featuring software used for development of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products ] * Research, product development and quality control services in the field of proteins, antibodies, microorganisms and cells, and consultancy relating thereto; research and development services in the field of antibody technology; biomedical research services; [ design and development of medical technology; ] research and development in the field of biotechnology; pharmaceutical research and development; [ conducting clinical trials for others in the field of pharmaceutical products; clinical trials for others; ] technical project studies in the field of monoclonal antibodies for medical [ or veterinary ] purposes and pharmaceutical products; technical research in the field of monoclonal antibodies for medical [ or veterinary ] purposes and pharmaceutical products; technical project planning in the field of monoclonal antibodies for medical [ or veterinary ] purposes and pharmaceutical products; research and development of new products for others [ ; design and development of computer software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; providing temporary use of non-downloadable business software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; rental of computer software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; cloud computing featuring software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals * ]

[ Monoclonal antibodies for medical or veterinary purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; peptides and proteins for medical or veterinary purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; biological and chemical preparations and reagents for medical or veterinary purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; medicines for human purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; medicines for dental purposes, namely, for infectious diseases, neurological diseases or inflammatory diseases; medicines for veterinary purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; medicinal preparations, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; living cells for manufacturing monoclonal antibodies used for medical purposes; cell lines for manufacturing monoclonal antibodies used for medical purposes; living cells for manufacturing monoclonal antibodies used for veterinary purposes; cell lines for manufacturing monoclonal antibodies used for veterinary purposes; biological tissue cultures for medical purposes, namely, for cultivating living cells or cell lines used for manufacturing monoclonal antibodies; surgical implants comprised of living tissues; biological implants, namely, a vital processed human or animal connective tissue; disinfectants for hygiene purposes; sanitary sterilising preparations; biocides; preparations for destroying vermin ]

Filing History

COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
Feb 15, 2026 REM4
INTERNATIONAL REGISTRATION RENEWED
Apr 24, 2025 RNWL
NEW REPRESENTATIVE AT IB RECEIVED
Apr 18, 2025 NREP
PARTIAL INVALIDATION PROCESSED BY THE IB
Apr 1, 2024 INNP
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Feb 26, 2024 INPS
INVALIDATION PROCESSED
Feb 26, 2024 INPC
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Feb 10, 2024 INPR
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
Jun 10, 2023 NA71
REGISTERED - PARTIAL SEC 71 ACCEPTED
Jun 10, 2023 71.P
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
May 29, 2023 APRE
TEAS SECTION 71 RECEIVED
Nov 15, 2022 ES71
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Feb 14, 2022 REM3
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
Mar 7, 2018 INNA
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Feb 23, 2018 INPR
FINAL DECISION TRANSACTION PROCESSED BY IB
Oct 28, 2017 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Sep 15, 2017 FICS
FINAL DISPOSITION PROCESSED
Sep 15, 2017 FIMP
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Aug 4, 2017 OPNX
CORRECTION UNDER SECTION 7 - PROCESSED
Jun 23, 2017 COC.
ASSIGNED TO PARALEGAL
Jun 6, 2017 PLGL
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
May 14, 2017 FICR
TEAS SECTION 7 REQUEST RECEIVED
Mar 9, 2017 ES7R
REGISTERED-PRINCIPAL REGISTER
Feb 14, 2017 R.PR
POST PUBLICATION AMENDMENT – NOT ENTERED
Feb 1, 2017 CHPN
ASSIGNED TO PETITION STAFF
Jan 31, 2017 APET
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 28, 2016 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Dec 28, 2016 OPNR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Dec 16, 2016 OPNX
TEAS POST PUBLICATION AMENDMENT RECEIVED
Dec 16, 2016 EPPA
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 29, 2016 NPUB
PUBLISHED FOR OPPOSITION
Nov 29, 2016 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Nov 9, 2016 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Nov 9, 2016 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 9, 2016 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Oct 27, 2016 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 13, 2016 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 24, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 23, 2016 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Sep 23, 2016 ERSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Sep 19, 2016 RCCK
ASSIGNED TO LIE
Sep 15, 2016 ALIE
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Mar 10, 2016 GNS3
LETTER OF SUSPENSION E-MAILED
Mar 10, 2016 GNSL
SUSPENSION LETTER WRITTEN
Mar 10, 2016 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 16, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 15, 2016 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 15, 2016 TROA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 15, 2016 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 15, 2016 REAP
REFUSAL PROCESSED BY IB
Sep 4, 2015 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 14, 2015 RFCS
REFUSAL PROCESSED BY MPU
Aug 14, 2015 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 14, 2015 RFCR
NON-FINAL ACTION WRITTEN
Aug 13, 2015 CNRT
ASSIGNED TO EXAMINER
Aug 8, 2015 DOCK
APPLICATION FILING RECEIPT MAILED
Jul 29, 2015 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 25, 2015 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 23, 2015 REPR